11th Annual PREDiCT Tumour Models London starts in:

Day
Hour
Minute
Second

Engineering Your Next Generation Tumour Models to Maximise Immuno-Oncology & Cellular Therapies Clinical Success

Join us to Supercharge your Development, Validation of Emerging Models & Refine Selection Strategy to Enhance Your Translational Insights in TME & Tumour Metastasis to Empower Your Clinical Design

As we continue to see exciting preclinical and clinical updates in novel combination immno-oncology and cell-based therapies from drug developers, including the likes of Editas Medicine, Sanofi, BMS, Basilea, demand for advanced, well characterised and validated in vivo and 3D models surges.  

After 2 years of disruption, we are excited to bring the 11th Tumour Models London back to serve drug developers, leading academics and model providers this December. This industry-led summit is the only forum dedicated to Preclinical and Translational scientists to engage and discuss strategies and technology advancements to overcome current model limitations, and more importantly, share novel model engineering and validation approaches to support clinical design.  

This much-anticipated in-person meeting will unite 120+ pioneers to help you 

Your 2022 Unmissable Case Studies:

  • Cresendo Biologics shares their challenges and solutions for in vivo modelling the immunological activity of ni- and multi-specific therapeutics, and defining biomarker endpoints from mouse models to guide clinical decisions
  • ImCheck Therapeutics reveals their experience in preclinical models for gamma delta T-cell therapy in cell-mediated antitumor immune response, and how to define the best combination strategies
  • Ichnos Sciences Biotherapeutics SA discuss their in vivo strategy to improve T-Cell therapy clinical success, and how to define the translational relevance of different datasets
  • Scenic Biotech assesses how to optimise TME targeting, which can lead to patient stratification to improve clinical utility
  • Orion Corporation dissects how to recapitulate the human immune system for in humanised mice model
  • GSK and AstraZeneca fireside chat to delve into organ-on-a-chip, whether we can recapitulate the TME and evaluate the potential of creating an autologous environment

This is your must-attend tumour model summit to reconnect with fellows from Pfizer, Sanofi, and GSK, and propel your clinical progression with confidence in 2023!

"Tumour Models London was the best opportunity and comprehensive way to know the current models, techniques, and how to use them in non-clinical development projects."

Director, Preclinical Development, Apogenix GmbH, PREDiCT Series Attendee

"A nice opportunity to meet and interact with actors of preclinical immuno-oncology research."

Director, Preclinical Research, ImCheck Therapeutics, PREDiCT Series Attendee

"Improved my Knowledge."

Director, Preclinical Research. ImCheck Therapeutics, PREDiCT Series Attendee

"The event you have to be at, so not to miss the latest."

EuroPDX Manager, European Institute of Oncology, PREDICT Series Attendee

"It was a great event highlighting the importance of the microenvironment and physiological tumor settings in oncology."

Senior Researcher, Leiden University, PREDICT Series Attendee

"Inspiring and novel."

Head Of Laboratory, Exploratory Cancer Research, Translational Innovation Platform, Oncology-Immunooncology, Strategic Innovation, Merck and Co

PREDICT Series Attendee

"Seamless organization and platform functioning, amazing and very supportive staff, great science and vibe of the meeting."

Head of lab, Pathios Therapeutics

PREDICT Series Atendee

"It was a great experience and journey across new models to understand the tumour microenvironment and amazing new techniques to image. There were true novelties in the field and helpful service providers."

Head of Laboratory in Exploratory Cancer Research, Translational Innovation Platform Oncology, Merck & Co, PREDiCT Series Attendee

"It was a great experience and journey across new models to understand the tumour microenvironment and amazing new techniques to image. There were true novelties in the field and helpful service providers."

Head of Laboratory in Exploratory Cancer Research, Translational Innovation Platform Oncology, Merck & Co, PREDiCT Series Attendee

"An excellent conference to get up to speed on current approaches around pre-clinical tumour models."

Senior Principal Scientist, UCB Celltech, PREDiCT Series Attendee

Proud To Partner With: